- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Inflammation better CV risk predictor than LDL in patients intolerant to statins: CLEAR Outcomes analysis
![Inflammation better CV risk predictor than LDL in patients intolerant to statins: CLEAR Outcomes analysis Inflammation better CV risk predictor than LDL in patients intolerant to statins: CLEAR Outcomes analysis](https://medicaldialogues.in/h-upload/2023/11/08/750x450_224805-statin.webp)
USA: Inflammation is more powerful than cholesterol level for predicting future risk of cardiovascular (CV) events and death in high-risk patients intolerant to statins, a new analysis of the CLEAR Outcomes trial has shown.
"Inflammation assessed by high-sensitivity C-reactive protein (hs-CRP) predicted risk for future CV events and death more strongly than hyperlipidemia assessed by low-density lipoprotein cholesterol (LDLC)," the researchers reported in Circulation. "Bempedoic acid had similar efficacy compared with placebo for reducing CV risk across hsCRP and LDLC strata."
Previous studies have shown that among patients treated with statin therapy to guideline-recommended cholesterol levels, residual inflammatory risk assessed by hsCRP is at least as strong a predictor for future CV events as is residual risk assessed by LDLC. There is no clarity on whether these relationships are present among statin-intolerant patients with higher LDLC levels but they have implications for the choice of preventive therapies, including bempedoic acid, an agent that reduces both hs-CRP and LDLC.
Paul M. Ridker, Brigham and Women's Hospital, Boston, MA, and colleagues analyzed multinational CLEAR Outcomes, an ACL-Inhibiting Regimen Outcomes Trial. In the trial, 13970 statin-intolerant patients were randomly allocated to 180 mg of oral bempedoic acid daily or a matching placebo and followed for a 4-component composite of incident myocardial infarction (MI), coronary revascularization, stroke, or cardiovascular death, and all-cause mortality. Quartiles of increasingly baseline LDLC and hs-CRP were evaluated as predictors of future adverse events after adjustment for randomized treatment assignment and traditional risk factors.
Based on the study, the researchers reported the following findings:
- Compared with placebo, bempedoic acid reduced median hsCRP by 21.6% and mean LDLC levels by 21.1% at 6 months.
- Baseline hsCRP was significantly associated with the primary composite end point of major cardiovascular events (highest versus lowest hsCRP quartile; hazard ratio [HR], 1.43), all-cause mortality (HR, 2.21), and cardiovascular mortality (HR, 2.00).
- The relationship of baseline LDLC quartile (highest versus lowest) to future events was smaller in magnitude for the primary composite cardiovascular endpoint (HR, 1.19) and neutral for cardiovascular mortality (HR, 0.90) and all-cause mortality (HR, 0.95).
- Risks were high for those with elevated hsCRP irrespective of LDLC level.
- Bempedoic acid demonstrated similar efficacy in reducing cardiovascular events across all levels of hs-CRP and LDLC.
"Among statin-intolerant patients, vascular inflammation is a major determinant of atherosclerotic risk in a manner identical to that seen in statin-tolerant patients," the researchers wrote.
"These data suggest that targeting LDL-C alone is unlikely to completely reduce atherosclerotic risk and that inflammatory pathways have yet to be fully exploited for patient benefit.”
Reference:
Ridker PM, Lei L, Louie MJ, et al. Inflammation and cholesterol as predictors of cardiovascular events among 13 970 contemporary high-risk patients with statin intolerance. Circulation. 2023;Epub ahead of print.
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751